Tegileridine

Tegileridine is a drug which acts as a μ-opioid receptor agonist. It is closely related to compounds such as oliceridine, TRV734, and SHR9352, and shares a similar profile as a biased agonist selective for activation of the G-protein signalling pathway over β-arrestin 2 recruitment.[1]

Tegileridine
Clinical data
Trade names艾苏特
Legal status
Legal status
  • Rx in China
Identifiers
  • (1S,4S)-4-Ethoxy-N-[2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethyl]-1,2,3,4-tetrahydronaphthalen-1-amine
CAS Number
PubChem CID
Chemical and physical data
FormulaC28H38N2O2
Molar mass434.624 g·mol−1
3D model (JSmol)
  • CCO[C@H]1CC[C@@H](C2=CC=CC=C12)NCC[C@]3(CCOC4(C3)CCCC4)C5=CC=CC=N5
  • InChI=1S/C28H38N2O2/c1-2-31-25-13-12-24(22-9-3-4-10-23(22)25)29-19-16-27(26-11-5-8-18-30-26)17-20-32-28(21-27)14-6-7-15-28/h3-5,8-11,18,24-25,29H,2,6-7,12-17,19-21H2,1H3/t24-,25-,27+/m0/s1
  • Key:YUMLNLMFBWBKSK-OHSXHVKISA-N

In January 2024, tegileridine was approved in China for the treatment of moderate to severe pain after abdominal surgery.[2]

See also

References
  1. WO 2017063509, "Oxa spiro derivative, preparation method therefor, and applications thereof in medicines", published 10 April 2018, assigned to Jiangsu Hengrui Medicine Company and Shanghai Hengrui Pharmaceutical Company Ltd .
  2. Dhillon, Sohita (2024). "Tegileridine: First Approval". Drugs. doi:10.1007/s40265-024-02033-4.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.